Astellas Pharma US, Inc.
About Astellas Pharma US, Inc.
With revenues exceeding $2Bn and approximately 2,000 employees, Astellas Pharma US drives development efforts that offer innovative treatment of unmet medical needs and advancement of good health globally. Astellas is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the U.S., Astellas markets products in the areas of immunology, urology, anti-infectives, cardiovascular and dermatology. Our client’s primary products include the antifungal Mycamine, the vascular dilator Andenoscan, enlarged prostate treatment Flomax, and the organ transplant immunosuppressant Prograf. Astellas’ other products include overactive bladder treatment VESIcare and dermatological products Protopic and Amevive. Further expanding upon internal development efforts to enter the oncology space, in 2007 Astellas Pharma Inc acquired Agensys, a biotechnology company specializing in therapeutic antibody research and development. Agensys was founded by an experienced executive team, and renowned UCLA oncologists and cancer scientists to explore drug targets and therapeutic antibody development. By applying differential gene expression technology to human tissues Agensys has identified 30 proprietary targets in 14 cancer types. Astellas is committed to becoming one of the top ten, global pharmaceutical companies by 2015. Critical to this success will be our employees. As such, Astellas is equally committed to being the employer of choice within the pharma industry. Offering first class benefits, an outstanding work environment and challenging development opportunities at every turn, Astellas is a great company for top performers who want to make a difference and be recognized for their contributions.